Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Illustration: Rebecca Zisser/Axios
Americans on average are dying sooner, largely due to the country’s opioid epidemic. But a number of medical advances are helping people who have chronic diseases live longer.
What’s working: Medical researchers and venture capitalists told Axios that these drugs and treatments have immensely helped patients, or could change the face of medicine shortly.
- Hepatitis C drugs sold by Gilead Sciences and AbbVie essentially eradicate the virus in as few as two months, although side effects vary.
- Immunotherapy treatments, such as CAR-T, give patients the chance to fight off cancer with modified versions of their own immune cells.
- New gene therapies are attacking rare disorders, such as one treatment that reverses a rare form of blindness.
- Gene-modifying systems like CRISPR are giving scientists hope of treating disease at the DNA level.
- Newer diabetes treatments have been shown to slow the costly and crippling long-term disease.
Be smart: The price tags are huge, and we still don’t know about all of their long-term side effects. There are always tradeoffs in health policy, but a breakthrough drug or treatment may not be all that valuable if people can’t access or afford it.
Go deeper:
Experts divided on trend toward smaller, targeted clinical trials